CellCentric News and Activities
Presence
Headquarters: United Kingdom (UK)
Acquisition, funding and merger involving CellCentric.
- CellCentric has just announced a $220 Million fundraising (posted on May 6 2026).
- CellCentric has just announced a $120 Million fundraising (posted on May 19 2025).
Executives
View the org chart displaying its 28 main executives
Most searched biographies at CellCentric
- Will West, Chief Executive Officer and Director
- Jason Dinges, Chairman of the Board
- Andrew Hughes, Non-Executive Director
Popular executive movements at CellCentric
- Andy Fergus, Chief Development Officer, has left the company (posted on November 18 2025).
Create your alert
to follow the executive moves at CellCentric.
Healthcare
CellCentric has 3,493 competitors including UnitedHealth Group (United States (USA)), Kaiser Permanente (United States (USA)) and HCA (United States (USA)).
Popular M&A news in Healthcare
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Freeman Health System has acquired Northwest Health (posted on June 2 2026).
- Garner Health has just announced a $100 Million fundraising (posted on May 29 2026).
Popular contacts in Healthcare
News
Press releases by CellCentric
- CellCentric to Share Latest Inobrodib Phase II Data; Oral Presentation at ASH 2024 – CellCentricFDC40D06-9F76-4E8A-AF33-68251D6B17C15ED9A5DB-1645-4854-AFCE-FF80DBBE114FFDC40D06-9F76-4E8A-AF33-68251D6B17C18B1E0328-3F62-4701-A135-6606C5F74CC55ED9A5DB-1645-4
- CellCentric expands executive team with new Chief Development Officer – CellCentricFDC40D06-9F76-4E8A-AF33-68251D6B17C15ED9A5DB-1645-4854-AFCE-FF80DBBE114FFDC40D06-9F76-4E8A-AF33-68251D6B17C18B1E0328-3F62-4701-A135-6606C5F74CC55ED9A5DB-1645-4854-AFCE-FF80
- Press Releases – Page 5 – CellCentricFDC40D06-9F76-4E8A-AF33-68251D6B17C15ED9A5DB-1645-4854-AFCE-FF80DBBE114FFDC40D06-9F76-4E8A-AF33-68251D6B17C18B1E0328-3F62-4701-A135-6606C5F74CC55ED9A5DB-1645-4854-AFCE-FF80DBBE114F
- CellCentric Secures $35 Million Investment from RA Capital Management – CellCentricFDC40D06-9F76-4E8A-AF33-68251D6B17C15ED9A5DB-1645-4854-AFCE-FF80DBBE114FFDC40D06-9F76-4E8A-AF33-68251D6B17C18B1E0328-3F62-4701-A135-6606C5F74CC55ED9A5DB-1645-4854-AFCE-FF80
- CellCentric discloses significant new clinical data, demonstrating inobrodib’s efficacy in ongoing Phase I/IIa clinical trials – CellCentricFDC40D06-9F76-4E8A-AF33-68251D6B17C15ED9A5DB-1645-4854-AFCE-FF80DBBE114FFDC40D06-9F76-4E8A-AF33-68251D6B17C18B1E032
- CellCentric’s inobrodib’s novel mechanism: new data published in Cancer Cell – CellCentricFDC40D06-9F76-4E8A-AF33-68251D6B17C15ED9A5DB-1645-4854-AFCE-FF80DBBE114FFDC40D06-9F76-4E8A-AF33-68251D6B17C18B1E0328-3F62-4701-A135-6606C5F74CC55ED9A5DB-1645-4854-AF
- CellCentric secures further investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm – CellCentricFDC40D06-9F76-4E8A-AF33-68251D6B17C15ED9A5DB-1645-4854-AFCE-FF80DBBE114F70F65CDB-84D7-4DBF-B9A3-94D23EB869978B1E0328-3F
- CellCentric announces $25m strategic investment from Pfizer – CellCentricFDC40D06-9F76-4E8A-AF33-68251D6B17C15ED9A5DB-1645-4854-AFCE-FF80DBBE114F70F65CDB-84D7-4DBF-B9A3-94D23EB869978B1E0328-3F62-4701-A135-6606C5F74CC5
- CellCentric Granted FDA Orphan Drug Designation for Inobrodib (CCS1477) for the Treatment of Multiple Myeloma – CellCentricFDC40D06-9F76-4E8A-AF33-68251D6B17C15ED9A5DB-1645-4854-AFCE-FF80DBBE114F70F65CDB-84D7-4DBF-B9A3-94D23EB869978B1E0328-3F62-4701-A135-
- CellCentric receives FDA Fast Track designation for inobrodib for the treatment of patients with relapsed refractory multiple myeloma – CellCentricFDC40D06-9F76-4E8A-AF33-68251D6B17C15ED9A5DB-1645-4854-AFCE-FF80DBBE114F70F65CDB-84D7-4DBF-B9A3-94D23EB86997
- View more press releases Close
Social media about CellCentric
- CellCentric on Wikipedia, Google News & Yahoo Finance
- CellCentric on LinkedIn, X (Twitter) & YouTube
